AZD1152
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukaemia
Conditions
Acute Myeloid Leukaemia
Trial Timeline
Nov 1, 2007 → Aug 1, 2009
NCT ID
NCT00530699About AZD1152
AZD1152 is a phase 1 stage product being developed by AstraZeneca for Acute Myeloid Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00530699. Target conditions include Acute Myeloid Leukaemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukaemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00530699 | Phase 1 | Completed |
| NCT00497679 | Phase 1 | Terminated |
| NCT00497991 | Phase 1 | Completed |
| NCT00497731 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukaemia